Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment
Hyperglycemia in T2DM is based on three main mechanisms: insulin resistance, progressive β-cell dysfunction, and excess glucose production by the liver.The onset of T2DM is usually preceded by a long period of insulin resistance. Prescribing sugar drugs that affect different links of pathogenesis, r...
Guardado en:
Autores principales: | M. V. Shestakova, M. B. Antsiferov, A. S. Ametov, G. R. Galstyan, T. Y. Demidova, A. M. Mkrtumyan, N. A. Petunina |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e11b41f30f754ce09441600dfaac4c04 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Insulin-Sensitizer Pioglitazone Remodels Adipose Tissue Phospholipids in Humans
por: Juan P. Palavicini, et al.
Publicado: (2021) -
Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
por: Schwartz S
Publicado: (2010) -
Comparison Between Pioglitazone/Metformin Combination Therapy and Sitagliptin/Metformin Combination Therapy on the Efficacy in Chinese Type 2 Diabetic Adults Insufficiently Controlled with Metformin: Study Protocol of an Open-Label, Multicenter, Non-Inferiority Parallel-Group Randomized Controlled Trial
por: Zhang F, et al.
Publicado: (2021) -
Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holl, et al.
Publicado: (2014) -
Pioglitazone Ameliorates Acute Endotoxemia-Induced Acute on Chronic Renal Dysfunction in Cirrhotic Ascitic Rats
por: Szu-Yu Liu, et al.
Publicado: (2021)